TWI375572B - Novel dosage formulation - Google Patents
Novel dosage formulation Download PDFInfo
- Publication number
- TWI375572B TWI375572B TW095134853A TW95134853A TWI375572B TW I375572 B TWI375572 B TW I375572B TW 095134853 A TW095134853 A TW 095134853A TW 95134853 A TW95134853 A TW 95134853A TW I375572 B TWI375572 B TW I375572B
- Authority
- TW
- Taiwan
- Prior art keywords
- water
- pure
- pharmaceutical
- composition
- tablet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
1375572 九、發明說明: 【發明所屬之技術領域】 本發明係關於一種製備草本製劑組合物之新方法,且詳 言之係關於用於口服藥物之草本製劑組合物。 【先前技術】 口服劑型經設計以使活性化合物在其作用位點上充分可 用。藥物之生物可用性取決於若干參數,諸如該活性化合 物之物理化學性質、劑型以及生理因素。 由於生物可用性不足,因此由現代藥物發現所獲得之多 種物質仍存在問題《該等分子通常展現極低之水溶性及在 油中有限之溶解度。此外,多種物質展現顯著之食物效 應,意即當藥物與某些食物同時服用時,其可以減少所攝 取藥物之效力或降低食物養份之吸收的方式相互作用。另 外,維生素及草本補充劑與指定藥物一起服用可導致有宝 反應。 食物與藥物可如何相互作用之一些實例包括: •食品可加速或減慢藥物之作用; •削弱維生素及礦物質在體内之吸收; •刺激或抑制食慾; •藥物可改變在體内利用養份之方式。 現已發現一組下式之NK-1受體拮抗劑 114026.doc 11375572
其中: R 為低碳烷基、低碳烷氧基、齒素或三氟甲基; R 為鹵素或氫;且當P為1時,除以上取代基之外R1 可連同R形成-CH=CH-CH=CH·;
R2及R2各自單獨為氫、鹵素、三氟甲基、低碳烷氧基或 氰基; 且當η為1時,除以上取代基以外,r2及r2’可形成_ch=ch_ CH=CH-,其未經取代或經一或兩個選自低碳烷基或低碳 烷氧基之取代基取代; R及R 為氩、低碳烧基或連同所連接之碳原子一起形成 環虎基; R 為氫、·NiR^CHJnOH、-N(R5)S(0)2-低碳烧
基、-N(R5)S(0)2-苯基、_n=CH-N(R5)2、- r6_P广 咴 n(r5)c(o)r5、 W 或飞^ . R5 為氬、C3_6-環烧基、苄基或低碳烧基; r6 為氫、羥基、低碳烷基、-(CH2)nCOCHR5)、_ n(r5)co-低碳烧基、經基·低碳烧基、_ (CH2)nCN、-(CH2)nO(CH2)nOH、-CHO或含有 1至 4 個選自由氧、氮及硫組成之群之雜原子之5_或6_ 員雜環’且該環中之破原子之一係未經取代或經 114026.doc < B ) 氧土取代,該雜環係直接鍵結或經由伸烷基鍵 結至該分子之剩餘部分;
Λ 為環狀三級胺,其可含有一個選自由 氧、氮或硫組成之群之額外雜原子,其中該環中 存在之任何硫均為硫代或可氧化為亞砜或二氧化 硫,該環狀二級胺係經其直接連接至該分子之剩 餘部分或經連接子_(CH2)nN(R5)·連接; X 為 _C(0)N(R5)_、_(cH2)m0-、-(CH2)mN(R5)-、_ N(R5)C(0)-或-N(R5)(CH2)m-; n、P及q各自獨立為1至4 ;且 m 為1或2 ; 及其結晶形式之醫藥上可接受之酸加成鹽,該組物質實際 上係不溶於水(例如<0.0001 mg/ml)及在25時為模擬胃液 (例如0_08 mg/ml),其可調配為適合且可應用於人類患者 之劑型調配物。在該等化合物之前,該調配物可克服在模 擬腸液中實際上不溶之缺陷。較佳劑型調配物為含有400 mg活性成份之錠劑。 式I化合物為已知之化合物,且其在EP 1,〇35,115中描述 為用於治療CNS病症(諸如抑鬱症、焦慮症及嘔吐)之活性 NK1受體拮抗劑。 式I之較佳化合物為化合物2-(3,5-雙-三氟甲基-苯基)-N-甲基-N-(6-嗎啉-4-基-4·鄰-甲苯基-吡啶-3-基)異丁醯胺, 其具有結構式 114026.doc 1375572
且其展現上述不溶解性,意即,在水及pH 30_70之水性 緩衝溶液中<0.0001 mg/ml。 作為增加生物可用性及減少副作用(諸如在4〇〇爪§錠 幻中之食物效應)之主要目的,研究一種新型草本製劑
調配方法。已發現熱熔融擠出(HME)之方法解決上述問 題。 【發明内容】 本發明之目標為一種製備醫藥錠劑組合物之方法,其中 將式I之活性醫藥成份或其醫藥上可接受之酸加成鹽及水 溶性泊洛沙姆在與其他成份混合之前藉由熱熔融擠出共同 加工,且其中該錠劑組合物之後可由包含立即釋放型薄膜 塗覆系統及純水之組合物來塗覆。
已發現’其中活性成份及水溶性、泊洛沙姆(諸如泊洛沙 姆188 (L咖i F68))、鍵劑黏♦劑及潤濕劑為經由擠壓機 加工之僅有組份之熱熔融擠出(HME)方法,產生一種微晶 固體分散液,其具有低粒度、可接受顆粒分散性及在與其 他賦形性劑組合時產生具有所㈣物轉特徵线劑之溶 解特徵。 ’均可應用以下本文 用於實施方式及所附 < S ) 不管所討論之術語單獨或址合出現 所用通用術語之定義。必須注意,杏 114026.doc 1375572 申請專利範圍中時,除非本文另外明確指示,否則單數形 式之"一"及"該"均包括複數形式。 術語"低碳烷基"表示含有1至7個碳原子之直鏈或支鏈烷 基。低碳烷基之非限制性實例包括曱基、乙基、丙基、異 丙基、正丁基、異丁基、第三丁基及其類似物。 術語"伸烷基"意謂在任一端結合至基團之低碳烷基連接 子。伸烷基之非限制性實例包括亞甲基、#乙基伸丙基 及其類似物。
術語"低破烧氧基"表示經由氧原子連接之如上文所定義 之烧基。低碳⑤氧基之非限制性實例包括甲氧基、乙氧 基、丙氧基及其類似物。 術語"環院基"表示含有3至6個碳原子之飽和碳環基(例如 非芳環)。環烧基之非限制性實例包括環丙基、環丁基、 環戊基、環己基及其類似物。 術s吾”齒素”表不氣、峨、敗及淳。
加工助劑為藉由改良(例如)泊叙从从* U夕』如)流動性並避免黏著來改良調 配物之可製造性之賦形劑0一鍤 削 種加工助劑類型為"膠狀二 氧化碎",具有約15 nm粒度-纟% % & β 及之-人铽觀發煙二氧化矽。盆 輕的、疏鬆、青白色、無氣味、I ^ ,,、、味不含砂之非a讲私 末。在本㈣中㈣H氧切之㈣制=括
Aerosil 380及 Cab-0-Sil » ^ 錠劑填充劑/稀釋劑之非限制性實例包括 之澱粉衍生物、纖維素、鈣鹽、糖 么改質 酶及支駭粉㈤種肖冑料為由殿粉 甸糖之多醣)組成之物質。可 114026.doc •10· 1375572 用於本發明之一種澱粉類型為玉米澱粉。可用於本發明之 玉米澱粉之非限制性實例包括Pure-Cote、Pure-Bind、 Pure-Dent ' Pure-Gel ' Pure-Set ' Melojel ' Meritena ' Paygel55、Perfectamyl D6PH、Purity 21、Purity 826 及 Tablet White。 可用作錠劑填充劑/稀釋劑之一種纖維素類型為微晶纖 維素。"微晶纖維素"(MCC)為天然產生之聚合物,其包含 由1-4β糖苷鍵連接之葡萄糖單元。MCC可衍生自特殊級別 之α纖維素。可用於本發明之MCC之非限制性實例包括 Avicel、Vivapur、Vivacel、Emcocel。可用作鍵:劑填充劑 / 稀釋劑之一種糖醇類型為甘露糖醇。可用於本發明之甘露 糖醇之非限制性實例包括Parteck Μ 200。 在本發明中可使用不同類型之崩解劑,諸如NVP水可膨 脹性聚合物、交聯羧甲纖維素及纖維素衍生物。”NVP水 可膨脹性聚合物"為含有Ν-乙烯基吡咯啶酮(例如Ν-乙烯基-2-吡咯啶酮)之不溶性可膨脹之均或雜聚物。 '•醫藥上可接受之酸加成鹽"包含無機或有機酸之鹽,該 等酸諸如鹽酸、硝酸、硫酸、磷酸、檸檬酸、曱酸、反丁 烯二酸、順丁烯二酸、乙酸、丁二酸、酒石酸、甲磺酸、 對甲苯磺酸及其類似物。 "水溶性泊洛沙姆”為氧化乙烯(意即聚氧乙烯(ΡΟΕ))及氧 化丙烯(意即聚氧丙烯(POP))之嵌段共聚物,其溶於水中且 用作醫藥調配物中之潤濕劑。在本發明中有用之泊洛沙姆 之非限制性實例包括Lutro 1 F6 8 (泊洛沙姆18 8)。 114026.doc (5 1375572 "擠出"為在受控條件下藉由使原料強制通過沖模而將其 轉化為均一形狀及密度之產物的方法。 本發明提供一種包含熱熔融擠出物之組合物,該熱熔融 擠出物包含式I之化合物及水溶性泊洛沙姆。詳言之,本 發明提供一種包含熱熔融擠出物之組合物,該熱熔融擠出 物包含諸如2-(3,5-雙-三氟曱基-苯基)-N-曱基-N-(6-嗎啉-4-基-4-鄰-曱苯基-吡啶-3-基)異丁醯胺鹽酸鹽之式I化合物 及水溶性泊洛沙姆(諸如Lutrol F68)。
新型醫藥錠劑組合物包含: a) 式I之活性成份 30-60% b) 水溶性泊洛沙姆 10-20% c) 填充劑 20-30% d) 崩解劑 1-10% e) 加工助劑,及 0-5%,及 f) 助流劑 0-5%,及若必要
g) 立即釋放型薄膜塗覆系統 2-5%之錠劑重量 h)純水 代表性調配組合物之實例包含以下成份 mg/鍵劑 2-(3,5-雙-三氟曱基-苯基)-N-曱基-N-(6-嗎啉-4-基-4-鄰-曱苯基-吡啶-3-基)異丁醯胺鹽酸鹽 400.00 Lutrol F68 133.35 微晶纖維素(Avicel PHI 02) 162.65 Parteck M 200(甘露糖醇) 30.00 Polyplasdone XL 16.00 膠狀二氧化秒(Aerosil 380) 16.00 玉米澱粉 30.00 硬脂酸鎂 12.00 藥芯總重量 800.00 114026.doc -12- 1375572 代表性塗覆組合物之實例包含:
Opadry Yellow 03K 12429 25.00 純水 131.25 經薄膜塗覆之錠劑總重量 825.00 【實施方式】 製造方法: 根據本發明製備醫藥鍵劑組合物之方法包含以下步驟: 1) 將活性醫藥成份與水溶性泊洛沙姆摻合, 2) 使用步驟1之粉末摻合物製備熱熔融擠出物, 3) 為得到經研磨材料’使擠出之材料通過篩分機,藉此可 能必需一個以上之筛分步驟以獲得具有所要粒度範圍之材 料, 4) 將步驟3之經研磨撥出物以第一步驟與填充劑及崩解劑 摻合, 5) 藉由將步驟4之混合物與加工助劑及助流劑摻合來製備 最終摻合物,及 6) 將步驟5中製備之最終摻合物壓製為錠劑。 更特定而言’該方法包含以下步驟: - 將約5 〇 %之活性醫藥成伶/遂杯1@•里认人 市砜仂/樂物物質置於摻合器(例如 PK、Bin或Bohle混合器)中。 - 添加水溶性泊洛沙姆且接:S·.夭k y ,, π且钱耆添加該樂物物質之剩餘 物。 將材料混合約30分鐘。 114026.doc 1375572 - 使用料斗進料機(例如K-Tron Soder)將步驟3之粉末混 合物轉移至熱溶融擠出機(例如Lei stritz)中且使粉末混合 物通過熱熔融擠出機。 - 於室溫下收集熱熔融擠出產物。 - 其後’首先使擠出之材料通過篩分機(例如FitzMill裝 置)’其使用低速刀片向前通過3號篩且接著以中速刀片向 前通過2號篩。 - 將約50%之研磨材料與填充劑(例如Avicel pH 102或 Parteck Μ 200,在通過4〇號網篩之後)、玉米澱粉、崩解 劑(例如Polyplasdone XL)及其他賦形劑(例如Aerosil 380, 在通過12號網篩之後)一起置於PK摻合器或等效物中,且 其後添加剩餘研磨材料且混合30分鐘。 - 將約50%之粉末混合物移除且將助流劑(例如硬脂酸 鎖’在通過40號網篩之後)添加至摻合器中之剩餘材料 中’且再添加其餘粉末混合物並混合5分鐘,及 • 使用例如〇.738" X 0.344"橢圓形沖頭將最終摻合物壓 製為錠劑》 藥芯可如下進行塗覆: 1) 在不銹鋼容器中,將完全薄膜塗覆系統(例如〇padq Yellow)藉由混合45分鐘而分散於純水中直至完全分散以形 成塗覆懸浮液, 2) 將藥芯置於穿孔塗覆盤中且以45+/_5〇C之進風伴隨間歇 性晃動進行加熱直至廢氣達到40+/-5°C, 3) 其後入口溫度增加至60+/_yc,且由連續攪拌之塗覆懸 114026.doc 14 < « 1375572 洋液塗覆料並使用空氣噴射系統在每—鏡劑之乾燥基底 上塗覆確定量之薄膜塗層(大約2至5%之錠劑重量), 4)藉由晃動使經塗佈錠劑乾燥,直至水分含量小於2%,且 H旋劑冷卻至室溫並儲存於密封之雙層聚乙稀襯裏之容
114026.doc .15-
Claims (1)
1375572 第095134853號專利申請案 中文申請專利月) 、申請專利範圍: 十年 一種製備醫藥錠劑組合物之方法,4中)舌性成份2-;(3,5-雙·二氟甲基-苯基)-N-甲基-N-(6-嗎啉-4-基-4-鄰-甲苯基-吼咬-3-基)異丁醯胺或其醫藥上可接受之酸加成鹽及水 溶性泊洛沙姆(P〇l〇xamer)在與其他成份混合之前,藉由 熱溶融擠出共同加工,且其中該錠劑組合物之後可由包 3立即釋放型薄膜塗覆系統及純水之組合物來塗覆;且 其中該醫藥錠劑組合物包含:
30-60% 10-20% 20-30% M0% a) 活性成份 b) 水溶性泊洛沙姆 c) 填充劑 d) 崩解劑 e) 加工助劑,及 0-5%,及 f) 助流劑 0-5%,及若必要 g) 立即釋放型薄膜塗覆系統 2-5。/❶之錠劑重量
h) 純水》 2 ·如咕求項1之製備醫藥錢劑組合物之方法,其包含以 步驟: 1) 將該活性成份與水溶性泊洛沙姆掺合, 2) 使用步驟丨之該粉末摻合物製備熱熔融擠出物, 3) 為得到經研磨材料,使該擠出之材料通過筛分機, 可能需要-個以上之篩分步驟以獲得具有所要粒度範圍 之材料’ 4) 將步驟3之該經研磨擠出物以第一步驟與該(等)填充 114026-l0107l3.doc 1375572 劑及崩解劑摻合’ 5) 藉由將步驟4之該混合物與加工助劑及助流劑摻合來 製備最終摻合物,及 6) 將步驟5中製備之該最終摻合物壓製為錠劑。 3. 如請求項1之方法,其中該醫藥銳劑組合物含有400 mg 之活性成份。 4. 如請求項1之方法,其中該水溶性泊洛沙姆為氧化乙烯 (POE)或氧化丙烯(POP)之嵌段共聚物。 5. 如請求項4之方法’其中該水溶性泊洛沙姆為Lutrol F68 β 6.如請求項1之方法’其中該填充劑為玉米澱粉、微晶纖 維素及糖醇之混合物。 7·如求項6之方法’其中該填充劑為pure_c〇te或Pure-Bind 或 pUre_Dent 或 pure Gei 或 Pure-Set 或 Mei〇jei 或 Meritena 或 paygel55 或 perfectamyiD6pH 或 purity 21 或 y 826 或 Tablet White及 Avicel 或 Vivapur 或 Vivacel 或 EmC〇Cel及 Parteclc Μ 200。 8.如明求項丨之方法,其中該加工助劑為膠狀二氧化矽。 月求項8之方法,其中該加工助劑為Aerosil 380或Cab-Ο- S i 1 〇 10.如請求jg, 之方法’其中該崩解劑為p〇lyplasd〇ne XL。 1 1 ·如請 J5 1 .. 項1之方法,其中該助流劑為硬脂酸鎂。 12 ·如請灰j§ 1 、 之方法,其中該醫藥錠劑組合物包含: ** 2 - (3 s — ,雙·二氟甲基苯基)-N-甲基_N_(6_嗎啉_4_基_4· 114026-1010713.doc 1375572
鄰-曱苯基-吡啶-3-基)異丁醯胺鹽酸鹽 400.00 mg Lutrol F68 133.35 mg 微晶纖維素(Avicel PH102) 162.65 mg Parteck M 200(甘露糖醇) 30.00 mg Polyplasdone XL 16.00 mg 膠狀二氧化矽(Aerosil 380) 16.00 mg 玉米澱粉 30.00 mg 硬脂酸鎂 12.00 mg Opadry Yellow 03K 12429 25.00 mg 純水 131.25 m卜
114026-1010713.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71979305P | 2005-09-23 | 2005-09-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200803922A TW200803922A (en) | 2008-01-16 |
TWI375572B true TWI375572B (en) | 2012-11-01 |
Family
ID=37671050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095134853A TWI375572B (en) | 2005-09-23 | 2006-09-20 | Novel dosage formulation |
Country Status (26)
Country | Link |
---|---|
US (3) | US20070071813A1 (zh) |
EP (1) | EP1928427B1 (zh) |
JP (2) | JP5523706B2 (zh) |
KR (1) | KR20080043852A (zh) |
CN (2) | CN101267808A (zh) |
AR (1) | AR056198A1 (zh) |
AT (1) | ATE453384T1 (zh) |
AU (1) | AU2006298898B2 (zh) |
BR (1) | BRPI0616108A2 (zh) |
CA (1) | CA2623237C (zh) |
DE (1) | DE602006011485D1 (zh) |
DK (1) | DK1928427T3 (zh) |
ES (1) | ES2335922T3 (zh) |
HK (1) | HK1198914A1 (zh) |
HR (1) | HRP20100111T1 (zh) |
IL (1) | IL189929A (zh) |
MY (1) | MY143784A (zh) |
NO (1) | NO340473B1 (zh) |
NZ (1) | NZ566419A (zh) |
PL (1) | PL1928427T3 (zh) |
PT (1) | PT1928427E (zh) |
RU (1) | RU2431473C2 (zh) |
SI (1) | SI1928427T1 (zh) |
TW (1) | TWI375572B (zh) |
WO (1) | WO2007039420A1 (zh) |
ZA (1) | ZA200802272B (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2395002T1 (sl) | 2005-11-08 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
JP5497633B2 (ja) | 2007-05-09 | 2014-05-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftrのモジュレーター |
DE102007027067A1 (de) * | 2007-06-12 | 2008-12-18 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat |
PL2639223T3 (pl) | 2007-12-07 | 2017-09-29 | Vertex Pharmaceuticals Incorporated | Sposób wytwarzania kwasów cykloalkilokarboksyamido-pirydyno-benzoesowych |
SI2225230T1 (sl) | 2007-12-07 | 2017-03-31 | Vertex Pharmaceuticals Incorporated | Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline |
KR20100134557A (ko) * | 2008-01-11 | 2010-12-23 | 씨아이피엘에이 엘티디. | 고체 약제학적 투여 제형 |
CA2931134C (en) | 2008-02-28 | 2019-07-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の医薬組成物およびその投与 |
EP2455068A1 (en) * | 2010-11-09 | 2012-05-23 | F. Hoffmann-La Roche AG | Pharmaceutical composition for treating HCV infections |
JP5917964B2 (ja) * | 2012-03-19 | 2016-05-18 | 富士ゼロックス株式会社 | 錠剤、錠剤の製造方法、錠剤管理装置、錠剤照合装置及びプログラム |
EP3067349B1 (en) | 2013-11-08 | 2018-02-28 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
RU2016122882A (ru) | 2013-11-12 | 2017-12-19 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
EP3505163B1 (en) * | 2014-09-08 | 2023-01-18 | University of Central Lancashire | Solid dosage form production |
RU2691136C2 (ru) | 2014-11-18 | 2019-06-11 | Вертекс Фармасьютикалз Инкорпорейтед | Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии |
CN104586770A (zh) * | 2014-12-30 | 2015-05-06 | 山东博迈康药物研究有限公司 | 一种盐酸帕唑帕尼的热熔挤出制剂及其制备方法 |
CN111344287B (zh) | 2017-11-14 | 2023-12-19 | 默沙东有限责任公司 | 作为吲哚胺2,3-双加氧酶(ido)抑制剂的新型取代的联芳基化合物 |
CN108159008B (zh) * | 2018-02-27 | 2021-03-23 | 河北化工医药职业技术学院 | 缬沙坦咀嚼片的制备方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1557420A (en) | 1977-03-10 | 1979-12-12 | Soc D Etudes Prod Chimique | Preparation of isobutyramide derivatives |
EP0089765A3 (en) | 1982-03-17 | 1984-05-23 | Smith Kline & French Laboratories Limited | Pyridine derivatives |
JPS60184008A (ja) * | 1984-03-02 | 1985-09-19 | Eisai Co Ltd | テオフイリンまたはアミノフイリン含有組成物 |
US4745123A (en) | 1986-02-18 | 1988-05-17 | Warner-Lambert Company | Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents |
GB8607313D0 (en) | 1986-03-25 | 1986-04-30 | Ici Plc | Pharmaceutical compositions |
GB8607312D0 (en) | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
CA1339423C (en) | 1988-09-14 | 1997-09-02 | Yuji Ono | Pyridine compounds and pharmaceutical use thereof |
US4994456A (en) | 1989-03-01 | 1991-02-19 | Nisshin Flour Milling Co., Ltd. | Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same |
US4973597A (en) | 1989-06-30 | 1990-11-27 | Eli Lilly And Company | Anticonvulsant agents |
HU207047B (en) | 1989-11-07 | 1993-03-01 | Richter Gedeon Vegyeszet | Process for producing new pyridine derivatives and pharmaceutical copositions comprising same |
US5364943A (en) | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
GB9021056D0 (en) | 1990-09-27 | 1990-11-07 | Pfizer Ltd | Antiarrhythmic agents |
GB9214120D0 (en) | 1991-07-25 | 1992-08-12 | Ici Plc | Therapeutic amides |
US5281420A (en) * | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
AU4718093A (en) * | 1992-07-31 | 1994-03-03 | Merck Sharp & Dohme Limited | Substituted amines as tachykinin receptor antagonists |
US5387595A (en) * | 1992-08-26 | 1995-02-07 | Merck & Co., Inc. | Alicyclic compounds as tachykinin receptor antagonists |
GB9305672D0 (en) | 1993-03-19 | 1993-05-05 | Wyeth John & Brother Ltd | Amide derivatives |
AU6807994A (en) | 1993-05-28 | 1994-12-20 | Taisho Pharmaceutical Co., Ltd. | Medicinal use of pyridine derivative |
US5506248A (en) * | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
NZ264063A (en) | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
EP1462450B1 (en) * | 1993-12-29 | 2007-06-13 | MERCK SHARP & DOHME LTD. | Substituted morpholine derivatives and their use as therapeutic agents |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
DE69523154T2 (de) | 1994-06-06 | 2002-06-06 | Warner Lambert Co | Tachykinin (nk1) rezeptor antagonisten |
AU2753195A (en) | 1994-06-24 | 1996-01-19 | Taisho Pharmaceutical Co., Ltd. | Pyridine derivative |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US6294537B1 (en) * | 1995-03-17 | 2001-09-25 | Sanofi-Synthelabo | Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools |
ATE242243T1 (de) | 1995-03-24 | 2003-06-15 | Takeda Chemical Industries Ltd | Zyklische verbindungen, ihre herstellung und ihre verwendung als tachykininrezeptorantagonisten |
DK0891332T3 (da) | 1996-03-29 | 2004-07-05 | Pfizer | 6-phenylpyridyl-2-aminderivater |
US5834472A (en) * | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
WO1998021185A1 (fr) | 1996-11-08 | 1998-05-22 | Sankyo Company, Limited | Arylurees ou derives d'arylmethylcarbamyle |
CO4920215A1 (es) | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
US5972938A (en) * | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
JPH11189546A (ja) | 1997-12-25 | 1999-07-13 | Saitama Daiichi Seiyaku Kk | 経皮吸収促進剤 |
JPH11189548A (ja) * | 1997-12-25 | 1999-07-13 | Toshio Sato | 無晶性医薬組成物及びその製造方法 |
WO2000050398A2 (en) | 1999-02-24 | 2000-08-31 | F. Hoffmann-La Roche Ag | Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists |
EP1035115B1 (en) * | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
DE60006340T2 (de) | 1999-11-29 | 2004-09-09 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid |
US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
WO2002089835A2 (en) * | 2001-05-03 | 2002-11-14 | F. Hoffmann-La Roche Ag | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
KR100810320B1 (ko) | 2005-06-16 | 2008-03-04 | 삼성전자주식회사 | 디지털 방송 재생기가 방송 중에 제공되는 전화번호를이용하여 발신하는 방법 및 그 디지털 방송 시스템 |
-
2006
- 2006-09-13 CN CNA2006800344737A patent/CN101267808A/zh active Pending
- 2006-09-13 AU AU2006298898A patent/AU2006298898B2/en active Active
- 2006-09-13 RU RU2008109823/15A patent/RU2431473C2/ru active
- 2006-09-13 JP JP2008531674A patent/JP5523706B2/ja active Active
- 2006-09-13 MY MYPI20080629A patent/MY143784A/en unknown
- 2006-09-13 PT PT06793473T patent/PT1928427E/pt unknown
- 2006-09-13 KR KR1020087006745A patent/KR20080043852A/ko not_active Application Discontinuation
- 2006-09-13 CA CA2623237A patent/CA2623237C/en active Active
- 2006-09-13 DE DE602006011485T patent/DE602006011485D1/de active Active
- 2006-09-13 ES ES06793473T patent/ES2335922T3/es active Active
- 2006-09-13 NZ NZ566419A patent/NZ566419A/en unknown
- 2006-09-13 BR BRPI0616108-1A patent/BRPI0616108A2/pt not_active Application Discontinuation
- 2006-09-13 EP EP06793473A patent/EP1928427B1/en active Active
- 2006-09-13 SI SI200630551T patent/SI1928427T1/sl unknown
- 2006-09-13 WO PCT/EP2006/066310 patent/WO2007039420A1/en active Application Filing
- 2006-09-13 AT AT06793473T patent/ATE453384T1/de active
- 2006-09-13 DK DK06793473.7T patent/DK1928427T3/da active
- 2006-09-13 PL PL06793473T patent/PL1928427T3/pl unknown
- 2006-09-13 CN CN201410122989.3A patent/CN103893145A/zh active Pending
- 2006-09-20 TW TW095134853A patent/TWI375572B/zh active
- 2006-09-21 AR ARP060104126A patent/AR056198A1/es not_active Application Discontinuation
- 2006-09-21 US US11/524,981 patent/US20070071813A1/en not_active Abandoned
-
2008
- 2008-03-04 IL IL189929A patent/IL189929A/en active IP Right Grant
- 2008-03-10 ZA ZA200802272A patent/ZA200802272B/xx unknown
- 2008-03-13 NO NO20081325A patent/NO340473B1/no unknown
-
2010
- 2010-03-02 HR HR20100111T patent/HRP20100111T1/hr unknown
- 2010-11-29 US US12/954,970 patent/US20110070303A1/en not_active Abandoned
-
2012
- 2012-10-19 JP JP2012231933A patent/JP2013049686A/ja active Pending
-
2013
- 2013-03-07 US US13/787,870 patent/US8852634B2/en active Active
-
2014
- 2014-12-09 HK HK14112383.4A patent/HK1198914A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI375572B (en) | Novel dosage formulation | |
TWI720943B (zh) | 以高用量含有4環性化合物的製劑 | |
AU2008327095B2 (en) | Amorphous form of heterocyclic compound, solid dispersion and medicinal preparation each comprising the same, and process for production of the same | |
US20060068007A1 (en) | Class of surfactant-like materials | |
TW200821298A (en) | Pharmaceutical compositions | |
JP2010509289A (ja) | チロシンキナーゼ阻害剤の経口投与用薬学的剤形 | |
CN1688291A (zh) | 含有固体药物分散体的即刻释放剂型 | |
TW200848056A (en) | Solid dispersion of a neurokinin antagonist | |
TW201442712A (zh) | 有機化合物之調配物 | |
KR102349893B1 (ko) | 제약 투여 형태 | |
EA030982B1 (ru) | Твердая галеновая форма с высоким содержанием фексофенадина и способ ее получения | |
JP2012171954A (ja) | カンデサルタンシレキセチルを安定化した組成物及びその製造方法 | |
CN106511291A (zh) | 一种盐酸阿考替胺缓释片剂及其制备方法 | |
JP2020090484A (ja) | エルロチニブを有効成分とする医薬錠剤 | |
TW202136257A (zh) | 非晶形激酶抑制劑調配物及其使用方法 | |
BG1677U1 (bg) | Фармацевтичен състав със стабилни частици на солифенацин или негова сол |